阿斯利康将以高达10亿美元收购比利时EsoBiotec,加码布局癌症业务

智通财经
17 Mar

智通财经APP获悉,英国制药商阿斯利康(AZN.US)同意以高达10亿美元的价格收购比利时生物技术公司EsoBiotec,以进一步增强其在癌症治疗领域的实力。

两家公司周一表示,阿斯利康将支付4.25亿美元的预付款,并在达到研发和监管里程碑时再支付高达5.75亿美元。

根据阿斯利康的说法,EsoBiotec的平台有可能增强免疫系统攻击癌症的能力,从而改变细胞疗法。它利用靶向病毒在人体内直接改造免疫细胞,有望将治疗时间从目前的数周缩短至几分钟。

EsoBiotec将成为阿斯利康的子公司,并在比利时继续运营。该交易预计将在第二季度完成。

在周一宣布的另一项癌症交易中,阿斯利康同意从Alteogen Inc.获得多种肿瘤资产的许可协议。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10